Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Intervacc AB logo — A new generation of vaccines based on fusions of recombinant...

Intervacc AB

A new generation of vaccines based on fusions of recombinant proteins

Founded 2001 Sweden Sweden 13 employees Grant Total: $30.00M Biotechnology, Health Care +1

General Information

Company Name Intervacc AB
Founded Year 2001
Location Sweden Sweden
Employees 13
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Intervacc AB. To contact Intervacc AB, visit intervacc.se.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Intervacc AB compare?

A PDF of Intervacc AB and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Intervacc AB soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Intervacc AB

Intervacc AB is a biotechnology company based in Sweden that focuses on developing a new generation of vaccines within animal health. The company's slogan, "A new generation of vaccines based on fusions of recombinant proteins," captures its innovative approach to vaccine development. Since its founding in 2001, Intervacc AB has been at the forefront of creating vaccines based on recombinant proteins to address the growing demand for effective and safe vaccines in animal healthcare. The company's commitment to leveraging recombinant proteins in vaccine development aligns with the increasing emphasis on safety and efficacy in the healthcare industry. This approach positions Intervacc AB at the intersection of biotechnology, health care, and pharmaceutical industries, indicating the potential for significant impact and growth. Recently, Intervacc AB received a grant investment from Vinnova on 17 August 2023, underscoring the confidence of investors in the company's innovative vaccine technologies. This investment not only provides financial support but also signifies external validation of the company's potential to make a meaningful contribution to animal health care. Overall, Intervacc AB's focus on developing vaccines based on recombinant proteins, coupled with its recent grant investment, positions the company as an exciting player in the biotechnology and animal health sectors. With a strong emphasis on safety and effectiveness, Intervacc AB is poised to make a significant impact on animal health and the broader pharmaceutical industry.

Business keywords: veterinary, vaccines, animal health, biotech, recombinant vaccines, microbiology

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Grant Undisclosed 1
Vinnova
Vinnova
17 Aug 2023
Venture Round kr30.00M 1
Knutsson Holdings
Knutsson Holdings
20 Dec 2010

Intervacc AB Alternatives & Competitors

View All Alternatives
Intervacc AB vs
Mazen Animal Health - Oral Vaccines
Mazen Animal Health - Oral Vaccines United States

Game-changing animal disease prevention with orally-delivered, RT stable, cost effective vaccines fo...

Series A
21 employees
Biotechnology, Health Care
Intervacc AB vs
Verovaccines
Verovaccines

VEROVACCiNES creates affordable animal vaccines through innovative technology, with the ability to c...

Series B
2-10 employees
Biotechnology, Health Care
Intervacc AB vs
KAICO Ltd.
KAICO Ltd. Japan

Changing the World with Silkworms

Series B
10 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Intervacc AB

A new generation of vaccines based on fusions of recombinant proteins
Intervacc AB was founded in 2001.
Intervacc AB is headquartered in Sweden.
Intervacc AB operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on veterinary, vaccines, animal health and biotech.
Intervacc AB has approximately 13 employees.
Intervacc AB has completed 2 funding rounds, raising a total of $30.00M. The latest funding stage is Grant.
Top alternatives and competitors to Intervacc AB include Mazen Animal Health - Oral Vaccines, Verovaccines, KAICO Ltd., Tréidlia Biovet, Abera Bioscience AB. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Intervacc AB and Mazen Animal Health - Oral Vaccines are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Intervacc AB, https://bouncewatch.com/company/intervacc-ab, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes